Spain’s Ministry of Health today (15 February) began the distribution among the regions of 483,000 new doses of the Pfizer-BioNTech vaccine, the first prophylaxis that was approved by the European Union and on which the current vaccination campaign continues to pivot in Spain.
The department, headed by Carolina Darias, said that the autonomous regions will receive a total of 1,779,570 doses of Pfizer-BioNTech this February a number will rise to 2,705,040 injectables in March, according to the forecasts made by health experts.
The Government has also guaranteed that this month Spain will receive a total of more than 4 million doses of the three vaccines that are currently authorised: BioNTech-Pfizer, AstraZeneca and Moderna.
Official calculations show that central goverment will go from supplying 4,002,145 doses scheduled for this February to at least 8.1 million injectables per month in the coming weeks and during the spring. With that rate of supply - official Ministry of Health numbers confirm - there would no longer be problems to use the 57 million doses that would remain at the end of February to immunise the 33 million people between March and September that would theoretically take Spain to the coveted 'herd immunity' target.
The Ministry is confident that Pfizer, which had to slow down its production in January in order to make changes to increase its manufacturing capacity, will not fail in its commitment to continue increasing the supply every month. Since last week the multi-national has also started producing the vaccine in the Marburg laboratories in central Germany, which it bought from the Swiss company Novartis last year. BioNTech, according to the information provided to the Government, plans to manufacture 250 million doses of its vaccine in Marburg in the first half of the year, which it expects to begin distributing at the end of March.